
OrthoPediatrics (KIDS) Stock Forecast & Price Target
OrthoPediatrics (KIDS) Analyst Ratings
Bulls say
OrthoPediatrics Corp has demonstrated a solid financial performance, reflected in a 50 basis points year-over-year increase in gross margin and a significant 280 basis points improvement in adjusted EBITDA margin. The company reported a 17.3% growth in Trauma & Deformity sales, surpassing expectations, alongside positive management indications of over 20% growth in OPSB during the third quarter, contributing to a strong outlook. Additionally, consistent revenue growth expectations of over 12% in the coming years, combined with anticipated operating leverage from new product introductions, position the company favorably for continued financial expansion.
Bears say
OrthoPediatrics Corp faces a challenging financial outlook due to several key factors, including a slowdown in revenue growth, with a decline from 15.7% in Q2 2025 to 12.2% in Q3 2025, indicating potential issues with sales and market demand. The company has also lowered its full-year guidance for 2025 to $233.5M-$234.5M, highlighting concerns over disappointing sales from newly acquired products and an overall decline in deployment of sales sets, decreasing from $17.2M TTM to $16.0M TTM. Furthermore, the risks associated with slower organic growth and productivity declines among distributors suggest that margin improvements and cash flow remain uncertain, raising further alarms regarding the company's financial health.
This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares